NCT05359341View on ClinicalTrials.gov

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

NACompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

September 20, 2021

Study Completion Date

January 10, 2022

Conditions
Diabete Type 2
Interventions
DRUG

Sitagliptin 50 mg

Adding on sitagliptin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.

DRUG

Empagliflozin 12.5 MG

Adding on empagliflozin to uncontrolled T2D Egyptian patients who are not controlled with diet, exercise and metformin with or without other OADs for 12 weeks.

DRUG

Sitagliptin 50 mg + Empagliflozin 12.5 MG

Adding on another 12 weeks of therapy of empagliflozin to sitagliptin 50mg group not well controlled (HbA1c 7-10%)

DRUG

Empagliflozin 12.5 MG + Sitagliptin 50 mg

Adding on another 12 weeks of therapy of sitagliptin 50mg to empagliflozin group not well controlled (HbA1c 7-10%)

Trial Locations (1)

Unknown

University of Sadat City, El Sadat

All Listed Sponsors
collaborator

Beni-Suef University

OTHER

lead

Sadat City University

OTHER

NCT05359341 - Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients? | Biotech Hunter | Biotech Hunter